ACCD:NSD-Accolade, Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 48.22

Change

+0.46 (+0.96)%

Market Cap

USD 3.09B

Volume

0.45M

Avg Analyst Target

USD 61.57 (+27.69%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CERN Cerner Corporation

+1.80 (+2.25%)

USD24.22B 30.78 14.71
TXG 10x Genomics, Inc

+0.31 (+0.17%)

USD20.12B N/A N/A
GDRX GoodRx Holdings, Inc

-0.22 (-0.69%)

USD12.60B 927.27 238.21
CHNG Change Healthcare Inc

-0.02 (-0.09%)

USD6.73B N/A 16.78
OMCL Omnicell, Inc

+2.49 (+1.70%)

USD6.33B 110.65 52.68
HQY HealthEquity, Inc

-2.00 (-2.70%)

USD6.17B 1,297.89 44.61
RCM R1 RCM Inc

+0.27 (+1.27%)

USD5.97B 72.63 30.76
INOV Inovalon Holdings, Inc

+0.32 (+0.85%)

USD5.92B 142.94 32.36
PGNY Progyny, Inc

-0.35 (-0.62%)

USD4.93B 95.85 260.69
PINC Premier, Inc

+0.31 (+0.87%)

USD4.36B 17.42 12.61

ETFs Containing ACCD

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.85% 61% D- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.85% 57% F 55% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 3.09B 63% D 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 96% A
Price/Book Ratio 7.08 37% F 21% F
Price / Cash Flow Ratio -122.58 90% A- 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.31% 32% F 32% F
Return on Invested Capital -21.29% 33% F 27% F
Return on Assets -7.82% 27% F 30% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.63 57% F 21% F
Short Percent 6.13% 33% F 32% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector